Technologies Driving Precision Medicine

  • ID: 4418553
  • Report
  • Region: Global
  • 47 Pages
  • Frost & Sullivan
1 of 3
Emerging Role of Chimeric Antigen Receptor (CAR) T-cell Treatment and Bispecific/Multi-specific T-cell Engaging Antibody Therapies

Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects.

This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.

Note: Product cover images may vary from those shown
2 of 3

1.0 Executive Summary
1.1 Research Scope
1.2 Research Methodology
1.3 Key Findings

2.0 Technologies Driving CAR T-cell Therapy
2.1 CAR T-cell Therapies Ideally Poised to Transform the Global Immunotherapy Landscape
2.2 CART Therapy Enables Improved Efficacy, Although Adverse Events May Continue to be a Cause For Concern
2.3 Antigen Identification and Enhanced Clinical Response are the Key Technology Drivers
2.4 Key Technology Restraints Comprise Critical Adverse Events and Reduced Efficacy in Solid Tumors

3.0 Analysis of Research, Funding, Clinical, and IP Landscapes
3.1 CAR T-cell Therapy Garners Growing Attention Across Research
3.2 Cancer Constitutes the Top Application Area For NIH-funded CAR T Therapy Projects
3.3 China Leads Global Clinical Trial Landscape Involving CAR T-cells
3.4 China Leads the Global Patent Landscape For CAR T-cell-based Innovations

4.0 Industry Trends and Future Perspectives for CAR T Therapies
4.1 Comparative Analysis of CAR T Platforms in Solid and Hematological Cancers
4.2 Transforming Immunotherapy With CAR T Technologies
4.3 Overview of Key CAR T Innovators
4.4 Future of CAR T Platform

5.0 Emerging Technological Landscape For Bispecific/Multi-specific Antibodies
5.1 Development of Bispecific/Multi-specific Antibody Platforms For Enhanced Therapeutic Applications
5.2 Bispecific/Multi-specific Platforms Offer Enhanced Therapeutic Benefits
5.3 Novel Antibody Platforms Improve Treatment Efficacy
5.4 Immunotoxicity Concerns Limit the Development of Bispecific/Multi-specific Antibody Platforms

6.0 Analysis of Research, Funding, Clinical, and IP Landscape
6.1 Growing Research Trends in Bispecific Antibody Platforms
6.2 Cancer is the Top Funding Area For NIH Projects Related to Bispecific/Multi-specific Therapeutic Antibodies
6.3 Most Clinical Studies For Bispecific/Multi-specific Antibodies Are Still in Early Phase
6.4 US Leads the IP Landscape For Innovations in Bispecific/Multi-specific Platforms

7.0 Industry Developments Across Bispecific and Multi-specific Antibody Therapeutics
7.1 Bispecific Antibody Treatment Platforms Score Over Conventional Monotherapies
7.2 Key Innovators Across Bispecific Therapies
7.3 Key Innovators Across Bispecific and Multi-specific Therapies

8.0 Growth Opportunities and Companies to Action
8.1 Growth Opportunity 1: Molecular Profiling Platforms
8.2 Growth Opportunity 2: CAR T-cell Therapy
8.3 Growth Opportunity 3: Bispecific/Multi-specific Antibodies
8.4 Strategic Imperatives for Success and Growth

9.0 Appendix
9.1 Summary of Key Contacts
Legal Disclaimer

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown